Sungho Bea, PharmD, PhD

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• 1A-05 - End-stage renal diseases associated with the use of SGLT2 inhibitors versus GLP-1 receptor agonists among individuals with metabolic dysfunction-associated steatotic liver disease: A nationwide cohort study

  Sunday, August 24, 2025
  11:30 AM - 11:45 AM ET

• 1E-02 - Risk of Opioid Overdose Associated with Concurrent Use of Hydrocodone and CYP3A4-inhibiting Calcium Channel Blockers

  Sunday, August 24, 2025
  10:45 AM - 11:00 AM ET

• 1E-03 - Opioid Overdose Associated With Concomitant Use of Hydrocodone And Selective Serotonin Reuptake Inhibitors

  Sunday, August 24, 2025
  11:00 AM - 11:15 AM ET

• 3F-06 - Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Patients with Venous Thromboembolism

  Monday, August 25, 2025
  9:30 AM - 9:45 AM ET